Last reviewed · How we verify
Injected Bupivacaine intraperitoneally
Bupivacaine injected intraperitoneally blocks sodium channels in nerve fibers within the peritoneal cavity, providing local anesthesia and analgesia to abdominal tissues.
Bupivacaine injected intraperitoneally blocks sodium channels in nerve fibers within the peritoneal cavity, providing local anesthesia and analgesia to abdominal tissues. Used for Postoperative pain management following abdominal surgery.
At a glance
| Generic name | Injected Bupivacaine intraperitoneally |
|---|---|
| Also known as | Marcaine |
| Sponsor | Imperial College London |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Bupivacaine is a long-acting local anesthetic that penetrates nerve cell membranes and reversibly inhibits sodium influx, preventing depolarization and action potential propagation. When administered intraperitoneally, it anesthetizes visceral and parietal peritoneal nerves, reducing pain signaling from abdominal organs and tissues. This approach aims to provide sustained postoperative analgesia and reduce opioid requirements following abdominal surgery.
Approved indications
- Postoperative pain management following abdominal surgery
Common side effects
- Systemic toxicity (if absorbed in high concentrations)
- Peritoneal irritation
- Transient abdominal discomfort
Key clinical trials
- Retrolaminar Block Versus Intraperitoneal Block for Laparoscopic Cholecystectomy (NA)
- Efficacy of Adding Dexmedetomidine Versus Ibuprofen as an Adjuvant to Intraperitoneal Bupivacaine for Pain Control After Laparoscopic Gynecological Procedures (PHASE2, PHASE3)
- Clinical Trial of the Use of Intraperitoneal Local Anaesthetic (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: